| | 东财医药何玮。 | | --- | --- | | 时间 | 2025 年 8 月 27 日（星期三） | | 地点 | 电话会议 | | 上市公司接待人 | 董秘：洪贇飞；证券事务代表：史笑梦 | | 员姓名 | | | | 一、公司基本情况介绍 | | | 2025 年上半年，公司实现营业收入 20.17 亿元，同比下降 | | | 6.20%；其中成品药收入 11.75 亿元，同比下降 9.68%；原料药 | | | 收入 4.53 亿元，同比下降 9.59%；医疗器械收入 3.49 亿元， | | | 同比增长 12.01%。实现归母净利润 3.88 亿元，同比下降 3.54%； | | | 实现扣非净利润 3.60 亿元，同比增长 7.78%。公司持续锤炼经 | | | 营韧性，通过多维度策略组合筑牢经营基本盘。 | | | 二、投资者问答主要内容： | | | 问题一：地达西尼的销售进展？ | | | 答：2025 年上半年，在医保准入的助力下，公司围绕京诺宁® | | | （地达西尼胶囊）的商业化布局持续深化，新增 400 多家重点 | | | 医疗机构准入资质，累计实现医院覆盖数量达 ...

Market Overview - On July 4, A-shares showed mixed performance with the three major indices fluctuating. The total trading volume reached 1.45 trillion yuan, an increase of 121 billion yuan compared to the previous trading day, with over 4,100 stocks declining [1] - Market focus was on stablecoins, digital currencies, and cross-border payment sectors, while banking and gaming sectors strengthened. Energy metals and small metals sectors experienced declines [1] Stock Performance - A total of 39 stocks hit the daily limit up, with 10 stocks achieving consecutive limit ups. The limit up rate was 65% (excluding ST and delisted stocks) [3] - Notable stocks included Chengbang Co., which saw a significant drop after hitting the limit up, while innovative drug concept stock Seli Medical achieved a limit up for the fourth consecutive day [3] Key Stocks and Trading Data - **Shenzhou Cell**: Increased by 16.46% with a trading volume of 20.17 million shares and a total transaction value of 1.63 billion yuan. Institutional net buying amounted to 156 million yuan [18] - **Jingxin Pharmaceutical**: Rose by 10.02% with a trading volume of 8.74 million shares and a total transaction value of 1.49 billion yuan. The company focuses on innovative drugs and medical devices [9][10] - **Hengbao Co.**: Engaged in financial technology and digital currency, with a focus on expanding overseas markets. The company reported overseas revenue of 93.62 million yuan, accounting for 10.37% of total revenue [12] - **Jingbeifang**: Engaged in stablecoin and digital currency sectors, recently signed a strategic cooperation agreement to enhance financial technology innovation [15] Institutional Trading - The top three net buying stocks by institutions were Shenzhou Cell, Hengbao Co., and Nanling Technology, with net purchases of 156 million yuan, 98.35 million yuan, and 91.73 million yuan respectively [6] - The top three net selling stocks were Haoshanghao, Jingbeifang, and Yingfangwei, with net sales of 110 million yuan, 105 million yuan, and 72.72 million yuan respectively [6] Summary of Key Companies - **Jingxin Pharmaceutical**: Focuses on the mental health sector and has a first-class innovative drug expected to be listed in March 2024, with plans to enter the medical insurance payment directory [9][10] - **Hengbao Co.**: Involved in financial technology and digital security, with a focus on digital currency innovation and expanding into overseas markets [12] - **Jingbeifang**: Actively participates in the construction of key digital currency systems for major state-owned banks and aims to innovate in financial technology [15]

Core Viewpoint - The company reported a slight increase in revenue and net profit for 2024, but the performance was slightly below market expectations [2] Group 1: Financial Performance - The company achieved a revenue of 4.159 billion yuan in 2024, representing a year-on-year increase of 3.99% [2] - The net profit attributable to shareholders was 712 million yuan, up 15.04% year-on-year [2] - The non-recurring net profit was 647 million yuan, reflecting a year-on-year growth of 21.38% [2] - The operating cash flow was 726 million yuan, down 8.41% year-on-year [2] - The basic earnings per share (EPS) was 0.83 yuan [2] Group 2: Business Segments - The finished drug segment continued to grow, with revenue reaching 2.522 billion yuan, an increase of 8.42% year-on-year [3] - The innovative drug, Didasyn, was successfully included in the medical insurance directory, supporting future sales [3] - The raw material drug segment saw a revenue decline to 876 million yuan, down 8.37% year-on-year, primarily due to market fluctuations [4] - The medical device segment achieved revenue of 687 million yuan, growing by 7.84% year-on-year, despite challenges in the global market [4]